Embolotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Indication, By Procedure, By End User, By Region and Competition

Description

The Global Embolotherapy Market was valued at USD 3.67 Billion in 2022 and is expected to experience substantial growth in the forecast period, with a Compound Annual Growth Rate (CAGR) of 8.35% and expected to reach USD 5.99 Billion through 2028. Embolotherapy, a minimally invasive treatment that selectively restricts blood flow to specific areas, is gaining recognition and popularity globally. This endovascular procedure is utilized to occlude abnormal blood vessels, effectively controlling or stopping bleeding. In urgent cases of severe hemorrhage, Embolotherapy is emerging as a viable alternative to invasive surgery, particularly for cases like severe bleeding. Interventional radiologists perform this procedure in various clinical settings. The applications of Embolotherapy have expanded significantly, especially in cutting-edge procedures like prostatic artery embolization (PAE) for benign prostatic hyperplasia and gastric artery embolization (GAE) for weight loss. These procedures have proven to be effective in treating their respective conditions. For instance, PAE is performed globally to address lower urinary tract symptoms (LUTS) caused by BPH, with over 800 procedures annually. Embolotherapy is also used in managing chronic pain conditions, treating uterine fibroids, and addressing specific types of cancer, such as liver cancer.

Key Market Drivers

Growing Target Patient Population

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 3.67 Billion
Market Size 2028	USD 5.99 Billion
CAGR 2023-2028	8.35%
Fastest Growing Segment	Embolic Agents
Largest Market	North America

The prevalence of cardiovascular disease (CVD) and the increasing importance of successful treatments have led to a focus on research into effective interventions. Peripheral vascular diseases affected over 200 million individuals globally in 2017. With age, the prevalence of these diseases rises, particularly in those aged 80 and above. The demand for Embolotherapy devices is driven by its success rate, low postoperative complications, and the rising incidence of conditions like liver cancer and hepatocellular cancer. Liver cancer is among the most common cancers in men and women, with over 840,000 new cases diagnosed worldwide in 2018. Kidney cancer incidence rates have also increased, particularly in the United Kingdom. These trends contribute to the demand for Embolotherapy.

Rising Patient Preference for Minimally Invasive Procedures

The increasing preference for minimally invasive surgeries is driving the demand for procedures like Embolotherapy. Patients opt for these procedures due to reduced postoperative pain, fewer complications, shorter hospital stays, and faster recovery times. Techniques like Trans Arterial Chemo Embolization (TACE) are evolving as minimally invasive alternatives, revolutionizing treatments like hepatocellular carcinoma. Prostatic Artery Embolization (PAE) serves as a minimally invasive therapy for benign prostatic hyperplasia (BPH) and its associated symptoms. The growing preference for these procedures is expanding the embolotherapy market.

Funding & Investments by Government and Private Organizations

Adequate funding and investments drive research, development, and refinement of medical procedures like Embolotherapy. Positive trial results instill confidence in medical professionals and patients, driving demand for adoption. Training programs and medical education disseminate knowledge among professionals, leading to increased demand. Government funding and support influence insurance coverage and reimbursement policies, making Embolotherapy more accessible.

Technological Advancements in Embolotherapy Devices

Technological advancements in embolotherapy devices have improved precision, effectiveness, and minimally invasive qualities. Enhanced microcatheters, advanced imaging techniques, navigation systems, robotics, and visualization tools have transformed the field. These advancements improve procedural outcomes, patient safety, and recovery times. As technology evolves, the embolotherapy field will likely see further innovations enhancing these procedures.

Key Market Challenges

Stringent Regulations

Artificial embolization devices are classified as medical devices and are subject to stringent regulations. Regulatory classifications impact device approval and authorization, influencing the market landscape.

Lack Of Skilled Medical Professionals

A shortage of skilled professionals can limit access to embolotherapy treatments, affecting patient outcomes and increasing risks.

Key Market Trends

Increasing Acquisitions and Collaborations

Collaborations enhance research, development, accessibility, and awareness of embolotherapy. Collaborative efforts accelerate innovation and solutions tailored to diverse patient needs.

Advancement in Oncology

The need for innovative cancer treatments drives demand for personalized solutions like embolotherapy. Precision and minimal invasiveness make embolotherapy attractive in personalized oncology care.

Segmental Insights

Product Insights

The embolic agent segment dominates the market due to the increasing prevalence of conditions requiring microspheres, especially in hepatocellular carcinoma treatment.

End User Insights

Hospitals are the primary users of embolotherapy devices. The increasing utilization of minimally invasive procedures, growing healthcare provider purchasing power, and availability of reimbursements contribute to this segment's growth.

Regional Insights

North America

North America leads the market due to the prevalence of conditions requiring embolization, a well-established healthcare system, and ongoing advancements in embolic agents.

Asia-Pacific

The Asia-Pacific region is expected to experience the fastest growth due to increasing patient populations, government healthcare investments, and rising cancer incidence.

Key Market Players

Medtronic, PLC
Microport Scientific
Boston Scientific Corporation
Stryker
Terumo Corporation
Penumbra, Inc.
Sirtex (CDH)
Johnson & Johnson
Abbott Laboratories
Balt Group

Report Scope:

In this report, the Global Embolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Embolotherapy Market, By Product:

Embolic Agents
Microspheres
Liquid Embolic Agents
Coil
Microcatheters

Embolotherapy Market, By Indication:

Oncology
Vascular
Aneurysm
Urology
Nephrology

Embolotherapy Market, By Procedure:

TACE
TARE

Embolotherapy Market, By End User:

Hospital
Clinics
Ambulatory Surgery Centres

Embolotherapy Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Turkey
Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Embolotherapy Market.

Available Customizations:

Global Embolotherapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Embolotherapy Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Embolic Agents, Microcatheters)
  - 5.2.1.1. By Embolic Agents (Microspheres, Liquid Embolic Agents, Coil)
- 5.2.2. By Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology)
- 5.2.3. By Procedure (TACE, TARE)
- 5.2.4. By End User (Hospital, Clinics, Ambulatory Surgery Centres)
- 5.2.5. By Region
- 5.2.6. By Company (2022)
5.3. Market Map

6. North America Embolotherapy Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
  - 6.2.1.1. By Embolic Agents
- 6.2.2. By Indication
- 6.2.3. By Procedure
- 6.2.4. By End User
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Embolotherapy Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.1.1. By Embolic Agents
    - 6.3.1.2.2. By Indication
    - 6.3.1.2.3. By Procedure
    - 6.3.1.2.4. By End User
- 6.3.2. Canada Embolotherapy Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.1.1. By Embolic Agents
    - 6.3.2.2.2. By Indication
    - 6.3.2.2.3. By Procedure
    - 6.3.2.2.4. By End User
- 6.3.3. Mexico Embolotherapy Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.1.1. By Embolic Agents
    - 6.3.3.2.2. By Indication
    - 6.3.3.2.3. By Procedure
    - 6.3.3.2.4. By End User

7. Europe Embolotherapy Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
  - 7.2.1.1. By Embolic Agents
- 7.2.2. By Indication
- 7.2.3. By Procedure
- 7.2.4. By End User
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Embolotherapy Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.1.1. By Embolic Agents
    - 7.3.1.2.2. By Indication
    - 7.3.1.2.3. By Procedure
    - 7.3.1.2.4. By End User
- 7.3.2. United Kingdom Embolotherapy Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.1.1. By Embolic Agents
    - 7.3.2.2.2. By Indication
    - 7.3.2.2.3. By Procedure
    - 7.3.2.2.4. By End User
- 7.3.3. Italy Embolotherapy Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Product
    - 7.3.3.2.1.1. By Embolic Agents
    - 7.3.3.2.2. By Indication
    - 7.3.3.2.3. By Procedure
    - 7.3.3.2.4. By End User
- 7.3.4. France Embolotherapy Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.1.1. By Embolic Agents
    - 7.3.4.2.2. By Indication
    - 7.3.4.2.3. By Procedure
    - 7.3.4.2.4. By End User
- 7.3.5. Spain Embolotherapy Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.1.1. By Embolic Agents
    - 7.3.5.2.2. By Indication
    - 7.3.5.2.3. By Procedure
    - 7.3.5.2.4. By End User

8. Asia-Pacific Embolotherapy Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
  - 8.2.1.1. By Embolic Agents
- 8.2.2. By Indication
- 8.2.3. By Procedure
- 8.2.4. By End User
- 8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Embolotherapy Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.1.1. By Embolic Agents
    - 8.3.1.2.2. By Indication
    - 8.3.1.2.3. By Procedure
    - 8.3.1.2.4. By End User
- 8.3.2. India Embolotherapy Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.1.1. By Embolic Agents
    - 8.3.2.2.2. By Indication
    - 8.3.2.2.3. By Procedure
    - 8.3.2.2.4. By End User
- 8.3.3. Japan Embolotherapy Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.1.1. By Embolic Agents
    - 8.3.3.2.2. By Indication
    - 8.3.3.2.3. By Procedure
    - 8.3.3.2.4. By End User
- 8.3.4. South Korea Embolotherapy Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.1.1. By Embolic Agents
    - 8.3.4.2.2. By Indication
    - 8.3.4.2.3. By Procedure
    - 8.3.4.2.4. By End User
- 8.3.5. Australia Embolotherapy Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.1.1. By Embolic Agents
    - 8.3.5.2.2. By Indication
    - 8.3.5.2.3. By Procedure
    - 8.3.5.2.4. By End User

9. South America Embolotherapy Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
  - 9.2.1.1. By Embolic Agents
- 9.2.2. By Indication
- 9.2.3. By Procedure
- 9.2.4. By End User
- 9.2.5. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Embolotherapy Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.1.1. By Embolic Agents
    - 9.3.1.2.2. By Indication
    - 9.3.1.2.3. By Procedure
    - 9.3.1.2.4. By End User
- 9.3.2. Argentina Embolotherapy Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.1.1. By Embolic Agents
    - 9.3.2.2.2. By Indication
    - 9.3.2.2.3. By Procedure
    - 9.3.2.2.4. By End User
- 9.3.3. Colombia Embolotherapy Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.1.1. By Embolic Agents
    - 9.3.3.2.2. By Indication
    - 9.3.3.2.3. By Procedure
    - 9.3.3.2.4. By End User

10. Middle East and Africa Embolotherapy Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
  - 10.2.1.1. By Embolic Agents
- 10.2.2. By Indication
- 10.2.3. By Procedure
- 10.2.4. By End User
- 10.2.5. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Embolotherapy Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.1.1. By Embolic Agents
    - 10.3.1.2.2. By Indication
    - 10.3.1.2.3. By Procedure
    - 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Embolotherapy Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.1.1. By Embolic Agents
    - 10.3.2.2.2. By Indication
    - 10.3.2.2.3. By Procedure
    - 10.3.2.2.4. By End User
- 10.3.3. UAE Embolotherapy Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.1.1. By Embolic Agents
    - 10.3.3.2.2. By Indication
    - 10.3.3.2.3. By Procedure
    - 10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global Oral Clinical Nutrition Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Business Overview
15.2. Service Offerings
15.3. Recent Developments
15.4. Key Personnel
15.5. SWOT Analysis
- 15.5.1. Medtronic, PLC
- 15.5.2. Microport Scientific
- 15.5.3. Boston Scientific Corporation
- 15.5.4. Stryker
- 15.5.5. Terumo Corporation
- 15.5.6. Penumbra, Inc.
- 15.5.7. Sirtex (CDH)
- 15.5.8. Johnson & Johnson
- 15.5.9. Abbott Laboratories
- 15.5.10. Balt Group